Healthcare
Live Price
Offline$6.65
+0.00% today
Window Change
-11.39%
Window
May 29, 2026 → Jun 15, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 12 bars · May 29, 2026 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tobii Dynavox AB (publ) (TDVXF) is a Healthcare stock with a market cap of $8.68B and listed on OTC. The stock last traded around $6.65 and down 11.4% across the available one-year price window (May 29, 2026 → Jun 15, 2026). Baseline metrics include revenue growth of +25.1%, EPS growth of +12.9%, a dividend yield of 0.0%. What stands out right now is revenue +25.1%, EPS +12.9%, free cash flow -108.1% with operating margin 9.3% and ROIC 10.5%. Valuation already assumes a fairly strong business story at P/E 82.8 and price/sales 5.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TDVXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TDVXF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TDVXF Max Drawdown
-19.74%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TDVXF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$871.2M
-28.4% YoY
FY Net Income
$29.8M
-38.7% YoY
Free Cash Flow
-$230.8M
-949.1% YoY
Revenue Growth
+25.1%
EPS Growth
+12.9%
Gross Margin
67.8%
Net Margin
6.5%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.5B | 2.0B | 1.6B | 1.2B | 871M |
| Gross Profit | 1.7B | 1.4B | 1.1B | 788M | 570M |
| Operating Income | 254M | 229M | 155M | 82M | 60M |
| EBITDA | 481M | 428M | 317M | 118M | 92M |
| Net Income | 166M | 146M | 104M | 49M | 30M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 195M | 133M | 161M | 107M | 197M |
| Total Assets | 2.5B | 2.0B | 1.7B | 1.3B | 1.1B |
| Total Liabilities | 1.9B | 1.5B | 1.4B | 1.1B | 1.0B |
| Shareholder Equity | 603M | 454M | 298M | 211M | 140M |
| Total Debt | 1.1B | 791M | 773M | 628M | 607M |
| Net Debt | 909M | 658M | 612M | 522M | 409M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
137M
+41.9% YoY
Capital Expenditures
367M
-210.7% YoY
Free Cash Flow
231M
-949.1% YoY
Key ratios
Gross Margin
67.8%
Operating Margin
9.3%
Net Margin
6.5%
ROE
41.0%
Debt / Equity
2.60x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.